{{Expert needed|subject=藥學|time=2020-12-15T09:48:52+00:00}}
{{Drugbox
| verifiedrevid = 460111355
| IUPAC_name = 4-(5''H''-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
| image = Cyproheptadine.svg
| width = 175
| image2 = Cyproheptadine-Spartan-PM3-3D-balls.png
| width2 = 175
<!--Clinical data-->
| pronounce = ({{IPAc-en|ˌ|s|aɪ|p|r|oʊ|ˈ|h|ɛ|p|t|ə|d|iː|n}}{{refn|{{Dictionary.com|Cyproheptadine}}}}
| tradename = Periactin, others
| Drugs.com = {{drugs.com|monograph|cyproheptadine-hydrochloride}}
| MedlinePlus = a682541
| DailyMedID = Cyproheptadine
| pregnancy_AU = A
| pregnancy_US = B
| legal_AU  = S3
| legal_CA = OTC
| legal_UK = GSL
| legal_US = Rx-only
| legal_status=OTC
| routes_of_administration = [[Oral_administration|Oral]]
<!--Pharmacokinetic data-->
| protein_bound = 96 to 99%
| metabolism = [[Liver|Hepatic]],<ref name = DM>{{cite web|title=CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]|website=DailyMed|publisher=Boscogen, Inc.|date=November 2010|access-date=26 October 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4|format=PDF|archive-date=2013-07-04|archive-url=https://web.archive.org/web/20130704111546/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f90faaa3-f40f-4653-8fb8-144d61c6b1d4}}</ref><ref name = TGA>{{cite web|title=PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)|website=Aspen Pharmacare Australia|publisher=Aspen Pharmacare Australia Pty Ltd|date=17 November 2011|access-date=26 October 2013|url=http://www.aspenpharma.com.au/product_info/pi/Periactin_PI_17Nov11.pdf|archive-url=https://web.archive.org/web/20131029203732/http://www.aspenpharma.com.au/product_info/pi/Periactin_PI_17Nov11.pdf|archive-date=29 October 2013|url-status=dead}}</ref> mostly [[CYP3A4|CYP3A4]] mediated.
| elimination_half-life = 8.6 hours<ref name="pmid15083941">{{cite journal |vauthors=Gunja N, Collins M, Graudins A | title = A comparison of the pharmacokinetics of oral and sublingual cyproheptadine | journal = Journal of Toxicology. Clinical Toxicology | volume = 42 | issue = 1 | pages = 79–83 | year = 2004 | pmid = 15083941 | doi = 10.1081/clt-120028749| s2cid = 20196551 }}</ref>
| excretion = 糞便 (2–20%; of which, 34% as unchanged drug) 與 [[腎|腎]] (40%; none as unchanged drug)<ref name = DM/><ref name = TGA/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 129-03-3
| CAS_supplemental = {{CAS|969-33-5}} ([[hydrochloride|hydrochloride]])
| ATC_prefix = R06
| ATC_suffix = AX02
| PubChem = 2913
| IUPHAR_ligand = 277
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00434
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2810
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2YHB6175DO
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07765
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4046
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 516
<!--Chemical data-->
| C=21 | H=21 | N=1
| SMILES = c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JJCFRYNCJDLXIK-UHFFFAOYSA-N
}}
<!-- Definition and medical uses -->
'''塞浦西他啶'''（Cyproheptadine），或名'''賽庚啶 '''，是第一代[[抗組織胺藥|抗組織胺藥]]，具有[[抗膽鹼劑|抗乙醯膽鹼]]和[[局部麻醉|局部麻醉]]的功能。

<!-- Society and culture -->
它於1959年獲得[[專利|專利]]，並於1961年用於醫療使用。<ref name=Fis2006>{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=547 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA547 |language=en |access-date=2020-12-15 |archive-date=2021-08-29 |archive-url=https://web.archive.org/web/20210829224446/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA547 }}</ref>

==醫療使用==
[[File:Periactin.jpg|thumb]]
[[File:Cyproheptadine3Dan.gif|thumb]]]]

*塞浦西他啶（Cyproheptadine）用於治療過敏反應 (特別是[[過敏性鼻炎|花粉症]]).<ref>{{Cite web |url=https://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682541.html |title=MedlinePlus Drug Information: Cyproheptadine |access-date=2020-12-15 |archive-date=2008-10-01 |archive-url=https://web.archive.org/web/20081001222723/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682541.html }}</ref> 用於此目的證實有效，但是第二代[[抗組織胺藥|抗組織胺藥]]像是 {{link-en|ketotifen}} 與 [[氯雷他定|氯雷他定]]（loratadine）也有相同的結果，且副作用較少。<ref name=DeBruyne2017/>
*它也被用作偏頭痛的預防性治療。在2013年的一項研究中，開始治療後7至10天內，患者的偏頭痛發生率顯著降低。這些患者在服藥前偏頭痛發作的平均頻率為每月8.7次，開始治療後3個月降至每月3.1次。<ref name=DeBruyne2017>{{cite journal|last1=De Bruyne|first1=P|last2=Christiaens|first2=T|last3=Boussery|first3=K|last4=Mehuys|first4=E|last5=Van Winckel|first5=M|title=Are antihistamines effective in children? A review of the evidence|journal=Archives of Disease in Childhood|date=January 2017|volume=102|issue=1|pages=56–60|doi=10.1136/archdischild-2015-310416|pmid=27335428|s2cid=21185048}}</ref><ref>{{cite journal|last1=Saito|first1=Y|last2=Yamanaka|first2=G|last3=Shimomura|first3=H|last4=Shiraishi|first4=K|last5=Nakazawa|first5=T|last6=Kato|first6=F|last7=Shimizu-Motohashi|first7=Y|last8=Sasaki|first8=M|last9=Maegaki|first9=Y|title=Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences|journal=Brain & Development|date=May 2017|volume=39|issue=5|pages=386–394|doi=10.1016/j.braindev.2016.11.011|pmid=27993427|s2cid=34703034}}</ref> 在英國和其他一些國家/地區，藥品仿單上有此用法。
*它也被藥品「仿單核准適應症外的使用」在嬰兒{{link-en|週期性嘔吐症候群|cyclical vomiting syndrome}}的治療。這種用途的唯一證據來自回顧性研究。<ref>{{cite journal|last1=Salvatore|first1=S|last2=Barberi|first2=S|last3=Borrelli|first3=O|last4=Castellazzi|first4=A|last5=Di Mauro|first5=D|last6=Di Mauro|first6=G|last7=Doria|first7=M|last8=Francavilla|first8=R|last9=Landi|first9=M|last10=Martelli|first10=A|last11=Miniello|first11=VL|last12=Simeone|first12=G|last13=Verduci|first13=E|last14=Verga|first14=C|last15=Zanetti|first15=MA|last16=Staiano|first16=A|last17=SIPPS Working Group on|first17=FGIDs.|title=Pharmacological interventions on early functional gastrointestinal disorders|journal=Italian Journal of Pediatrics|date=16 July 2016|volume=42|issue=1|pages=68|doi=10.1186/s13052-016-0272-5|pmid=27423188|pmc=4947301}}</ref>
*塞浦西他啶（Cyproheptadine）有時被「仿單核准適應症外的使用」，以改善服用抗精神病藥物的患者的[[静坐不能|静坐不能]]。<ref name="Maudsley">{{cite book|last1=Taylor|first1=David|last2=Paton|first2=Carol|last3=Kapur|first3=Shitij|title=The Maudsley Prescribing Guidelines in Psychiatry|date=2015|publisher=John Wiley & Sons|isbn=9781118754573|page=85|url=https://books.google.com/books?id=Lb77CAAAQBAJ|language=en|access-date=2020-12-15|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828052754/https://books.google.com/books?id=Lb77CAAAQBAJ}}</ref>
*它也被藥品「仿單核准適應症外的使用」於治療各種皮膚病，包括{{link-en|精神性搔癢症|psychogenic pruritus}}|<ref>{{Cite book|last1=Szepietowski|first1=JC|last2=Reszke|first2=R|title=Psychogenic Itch Management|journal=Current Problems in Dermatology|date=2016|volume=50|pages=124–32|doi=10.1159/000446055|pmid=27578081|isbn=978-3-318-05888-8}}</ref>、藥物誘發的[[多汗症|多汗症]]（出汗過多）<ref>{{cite journal |vauthors=Ashton AK, Weinstein WL |title=Cyproheptadine for drug-induced sweating |journal=[[American_Journal_of_Psychiatry|American Journal of Psychiatry]] |volume=159 |issue=5 |pages=874–5 |date=May 2002 |pmid=11986151 |doi=10.1176/appi.ajp.159.5.874-a |url=http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=11986151 |access-date=2020-12-15 |archive-date=2012-03-19 |archive-url=https://web.archive.org/web/20120319232405/http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=11986151 }}</ref>，以及預防{{link-en|表淺性單純性水疱性表皮鬆解症|Epidermolysis bullosa simplex}}的水皰形成。<ref>{{cite journal|last1=Pfendner|first1=Ellen G.|last2=Bruckner|first2=Anna L.|title=Epidermolysis Bullosa Simplex|journal=GeneReviews|date=October 13, 2016|pmid=20301543|url=https://www.ncbi.nlm.nih.gov/books/NBK1369/|access-date=2020-12-15|archive-date=2020-10-22|archive-url=https://web.archive.org/web/20201022072312/https://www.ncbi.nlm.nih.gov/books/NBK1369/}}</ref>
*該藥物的作用之一是[[食慾|食慾]]增加和體重增加，這導致該藥物在消瘦的兒童以及[[囊腫性纖維化|囊腫性纖維化]]患者中用於此目的（在美國為「仿單核准適應症外的使用」）。<ref>{{Cite web |url=https://www.vademecum.es/principios-activos-ciproheptadina%2C+estimulante+del+apetito-a15+m1 |title=Ciproheptadina, estimulante del apetito (Cyproheptadine, appetite stimulant) |access-date=2020-12-15 |archive-date=2020-10-24 |archive-url=https://web.archive.org/web/20201024153640/https://www.vademecum.es/principios-activos-ciproheptadina%2C+estimulante+del+apetito-a15+m1 }}</ref><ref>{{Cite web |url=https://www.caillon.com.uy/productos_ventana.php?id=39 |title=Bioplex NF |access-date=2020-12-15 |archive-date=2018-04-18 |archive-url=https://web.archive.org/web/20180418162117/https://www.caillon.com.uy/productos_ventana.php?id=39 }}</ref><ref name=cyapp>{{cite journal |authors=Harrison ME, Norris ML, Robinson A, Spettigue W, Morrissey M, Isserlin L|title=Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review. |date=2019 |journal=Appetite|volume=137 |pages=62–72 |doi=10.1016/j.appet.2019.02.012 |pmid=30825493|s2cid=72333631 }}</ref>
*它也使用在「仿單核准適應症外的使用」治療中度至重度[[血清素综合症|血清素综合症]]，與使用{{link-en|血清素類|serotonergic}}藥物有關的複雜症狀，像是[[选择性5-羟色胺再摄取抑制剂|选择性5-羟色胺再摄取抑制剂]] (與[[单胺氧化酶抑制剂|单胺氧化酶抑制剂]])，以及在血清素產生的[[類癌|類癌]]腫瘤導致血液中5-羥色胺升高的案例。<ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref><ref>{{cite journal|last1=Iqbal|first1=MM|last2=Basil|first2=MJ|last3=Kaplan|first3=J|last4=Iqbal|first4=MT|title=Overview of serotonin syndrome|journal=Annals of Clinical Psychiatry|date=November 2012|volume=24|issue=4|pages=310–8|pmid=23145389}}</ref>

==副作用==
副作用包括：<ref name = DM/><ref name = TGA/>

{{Div col}}
* 鎮靜和困倦（通常是短暫的）Sedation and sleepiness (often transient)
* 頭暈 Dizziness
* 協調不佳 Disturbed coordination
* 混亂 Confusion
* 躁動不安 Restlessness
* Excitation
* 緊張 Nervousness
* 震顫 Tremor
* 易怒 Irritability
* 失眠 Insomnia
* 感覺異常 Paresthesias
* 神經炎 Neuritis
* 抽搐 Convulsions
* 欣快感 Euphoria
* 幻覺 Hallucinations
* 歇斯底里 Hysteria
* 模糊 Faintness
* 皮疹和水腫的過敏表現 Allergic manifestation of rash and edema
* 發汗 Diaphoresis
* 蕁麻疹 Urticaria
* 對光敏感 Photosensitivity
* 急性迷路炎 Acute labyrinthitis
* 複視（雙眼） Diplopia (seeing double)
* 眩暈 Vertigo
* 耳鳴 Tinnitus
* 低血壓 Hypotension (low blood pressure)
* Palpitation
* Extrasystoles
* 過敏性休克 Anaphylactic shock
* 溶血性貧血 Hemolytic anemia
* 諸如[[白细胞减少症|白细胞减少症]]，[[粒細胞缺乏症|粒細胞缺乏症]]和[[血小板減少症|血小板減少症]]等血液異常 Blood dyscrasias such as [[leukopenia|leukopenia]], [[agranulocytosis|agranulocytosis]] and [[thrombocytopenia|thrombocytopenia]]
* 膽汁淤積 Cholestasis
* 對肝臟的影響：
** [[肝炎|肝炎]] Hepatitis
** [[黄疸|黄疸]] Jaundice
** [[肝功能衰竭|肝功能衰竭]] Hepatic failure<ref>{{cite journal|last1=Chertoff|first1=Jason|title=Cyproheptadine-Induced Acute Liver Failure|journal=ACG Case Reports Journal|date=8 July 2014|volume=1|issue=4|pages=212–213|doi=10.14309/crj.2014.56|pmc=4286888|pmid=25580444}}</ref>
** 肝功能異常 Hepatic function abnormality
* 上腹窘迫 Epigastric distress
* [[食欲不振|食欲不振]] Anorexia
* 噁心 Nausea
* 嘔吐 Vomiting
* 腹瀉 Diarrhea
* [[Anticholinergic|Anticholinergic]] side effects such as:
** 視力模糊 Blurred vision
** 便秘 Constipation
** 口腔乾燥症（口乾） Xerostomia (dry mouth)
** 心動過速（高心率）Tachycardia (high heart rate)
** [[尿瀦留|尿瀦留]] Urinary retention
** Difficulty passing urine
** 鼻塞 Nasal congestion
** 鼻或喉嚨乾燥 Nasal or throat dryness
* 頻尿 Urinary frequency
* 早期月經 Early menses
* 支氣管分泌物增厚 Thickening of bronchial secretions
* 胸悶氣喘 Tightness of chest and wheezing
* 疲勞 Fatigue
* 寒意 Chills
* 頭痛 Headache
* 食慾增加 Increased appetite
* 體重增加 Weight gain
{{Div col end}}

===用藥過量===
過量使用時，有時建議使用[[活性炭|活性炭]]進行洗胃。這些症狀通常表明中樞神經系統抑制（或在某些情況下相反地刺激中樞神經系統）和過度的抗膽鹼能副作用。小鼠的半數致死量([[LD50|LD<sub>50</sub>]])為 123 mg/kg，，大鼠的半數致死量為 295 mg/kg 。<ref name = DM/><ref name = TGA/>

==藥理==

===藥效學===
{| class="wikitable floatright" style="width:30em; font-size:small;"
|+ Cyproheptadine<ref name="PDSP">{{cite web|url=https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=cyproheptadine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query|title=PDSP K<sub>i</sub> Database|author1=Roth, BL|author2=Driscol, J|website=Psychoactive Drug Screening Program (PDSP)|publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health|access-date=14 August 2017|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828052721/https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=cyproheptadine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site
! K<sub>i</sub> (nM){{efn|[[平衡常数|平衡常数]]越小，藥物與位點的結合越强。}}
! Action{{efn|{{hlist|class=inline|↑促效劑|↓抗拮劑}}}}
! Species
! Ref.
|-
| [[Histamine_H1_receptor|H<sub>1</sub>]] || 0.06 || ↓ || Human ||
|-
| [[Histamine_H2_receptor|H<sub>2</sub>]] || {{abbr|ND|No data}} ||  || {{abbr|ND|No data}} ||
|-
| [[Histamine_H3_receptor|H<sub>3</sub>]] || >10,000 ||  || Human ||
|-
| [[Histamine_H4_receptor|H<sub>4</sub>]] || 202 ||  || Human ||
|-
| [[Muscarinic_acetylcholine_receptor_M1|M<sub>1</sub>]] || 12 || ↓ || Human ||
|-
| [[Muscarinic_acetylcholine_receptor_M2|M<sub>2</sub>]] || 7 || ↓ || Human ||
|-
| [[Muscarinic_acetylcholine_receptor_M3|M<sub>3</sub>]] || 12 || ↓ || Human ||
|-
| [[Muscarinic_acetylcholine_receptor_M4|M<sub>4</sub>]] || 8 || ↓ || Human ||
|-
| [[Muscarinic_acetylcholine_receptor_M5|M<sub>5</sub>]] || 11.8 || ↓ || Human ||
|-
| [[5-HT1A_receptor|5-HT<sub>1A</sub>]] || 59 ||  || Human ||
|-
| [[5-HT2A_receptor|5-HT<sub>2A</sub>]] || 1.67 || ↓ || Human ||
|-
| [[5-HT2B_receptor|5-HT<sub>2B</sub>]] || 1.54 || ↓ || Human ||
|-
| [[5-HT2C_receptor|5-HT<sub>2C</sub>]] || 2.23 || ↓ || Human ||
|-
| [[5-HT3_receptor|5-HT<sub>3</sub>]] || 228 ||  || Mouse ||
|-
| [[5-HT6_receptor|5-HT<sub>6</sub>]] || 142 ||  || Human ||
|-
| [[5-HT7_receptor|5-HT<sub>7</sub>]] || 123 ||  || Human ||
|-
| [[Dopamine_D1_receptor|D<sub>1</sub>]] || 117 ||  || Human ||
|-
| [[Dopamine_D2_receptor|D<sub>2</sub>]] || 112 || ↓ || Human ||
|-
| [[Dopamine_D3_receptor|D<sub>3</sub>]] || 8 ||  || Human ||
|-
| {{abbrlink|SERT|Serotonin transporter}} || 4,100 ||  || Rat ||
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 290 ||  || Rat ||
|-
| {{abbrlink|DAT|Dopamine transporter}} || {{abbr|ND|No data}} ||  || {{abbr|ND|No data}} ||
|- class="sortbottom" 
| colspan="5" style="word-wrap:break-word;" | {{noteslist}}
|}

Cyproheptadine is a very potent [[antihistamine|antihistamine]] or [[receptor_antagonist|antagonist]] of the [[H1_receptor|H<sub>1</sub> receptor]]. At higher concentrations, it also has [[anticholinergic|anticholinergic]], [[antiserotonergic|antiserotonergic]], and [[antidopaminergic|antidopaminergic]] activities. Of the [[serotonin_receptor|serotonin receptor]]s, it is an especially potent antagonist of the [[5-HT2_receptor|5-HT<sub>2</sub> receptor]]s, and this underlies its effectiveness in the treatment of [[serotonin_syndrome|serotonin syndrome]].

Cyproheptadine is known to be an [[receptor_antagonist|antagonist]] or [[inverse_agonist|inverse agonist]] of all of the [[receptor_(biochemistry)|receptor]]s listed in the adjacent table.<ref name="PDSP" />

塞浦西他啶（Cyproheptadine）的[[抗雄激素|抗雄激素]]活性較弱。<ref name="pmid9476091">{{cite journal | vauthors = Pucci E, Petraglia F | title = Treatment of androgen excess in females: yesterday, today and tomorrow | journal = Gynecol. Endocrinol. | volume = 11 | issue = 6 | pages = 411–33 | date = December 1997 | pmid = 9476091 | doi = 10.3109/09513599709152569 }}</ref>

===藥物代謝動力學===
塞浦西他啶（Cyproheptadine）[[口服给药|口服]]後吸收良好，血漿濃度峰值出現在1至3小時後。<ref name="MurrayDaly2011">{{cite book | author1 = Lindsay Murray | author2 = Frank Daly | author3 = David McCoubrie | author4 = Mike Cadogan | title = Toxicology Handbook | url = https://books.google.com/books?id=KDOeIldGWxQC&pg=PT388 | access-date = 27 November 2011 | date = 15 January 2011 | publisher = Elsevier Australia | isbn = 978-0-7295-3939-5 | page = 388 | archive-date = 2014-01-01 | archive-url = https://web.archive.org/web/20140101055857/http://books.google.com/books?id=KDOeIldGWxQC&pg=PT388 }}</ref>口服塞浦西他啶（Cyproheptadine）的[[生物半衰期|最終半衰期]]約為8小時。<ref name="pmid15083941" />

==化學==
塞浦西他啶（Cyproheptadine）是{{link-en|三環|Tricyclic}}{{link-en|苯並環庚烯|Benzocycloheptene}}，與{{link-en|吡唑替芬|Pizotifen}}和{{link-en|酮替芬|Ketotifen}}以及[[三環抗抑鬱藥|三環抗抑鬱藥]]密切相關。

==研究==
在一項規模較小的[[精神分裂症|精神分裂症]]患者中，輔助使用塞浦西他啶（Cyproheptadine）作為輔助治療，該患者的病情穩定且正在接受其他藥物治療。雖然注意力和口語流利性似乎有所改善，但這項研究規模太小，不足以概括。<ref>{{cite journal|last1=Buoli|first1=M|last2=Altamura|first2=AC|title=May non-antipsychotic drugs improve cognition of schizophrenia patients?|journal=Pharmacopsychiatry|date=March 2015|volume=48|issue=2|pages=41–50|doi=10.1055/s-0034-1396801|pmid=25584772}}</ref>在另兩項針對精神分裂症患者的試驗中，也已對其進行了佐劑研究，總共約有50人，並且似乎沒有效果。<ref name=Dabaghzadeh2012/>

已經進行了一些試驗，以觀察塞浦西他啶（Cyproheptadine）是否可以減輕SSRI和抗精神病藥引起的性功能障礙。<ref>{{cite journal|last1=Nunes|first1=LV|last2=Moreira|first2=HC|last3=Razzouk|first3=D|last4=Nunes|first4=SO|last5=Mari Jde|first5=J|title=Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review|journal=Journal of Sex & Marital Therapy|date=2012|volume=38|issue=3|pages=281–301|doi=10.1080/0092623X.2011.606883|pmid=22533871|s2cid=23406005}}</ref>

塞浦西他啶（Cyproheptadine）已被研究用於[[創傷後壓力症候群|創傷後壓力症候群]]（PTSD）。<ref name=Dabaghzadeh2012>{{cite journal|last1=Dabaghzadeh|first1=F|last2=Khalili|first2=H|last3=Ghaeli|first3=P|last4=Dashti-Khavidaki|first4=S|title=Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz |journal=Expert Opinion on Pharmacotherapy|date=December 2012|volume=13|issue=18|pages=2613–24|doi=10.1517/14656566.2012.742887|pmid=23140169|s2cid=25769557}}</ref>

==獸醫用途==
塞浦西他啶（Cyproheptadine）使用在貓的{{link-en|食慾刺激劑|appetite stimulant}}<ref>{{cite journal|last1=Agnew|first1=W|last2=Korman|first2=R|title=Pharmacological appetite stimulation: rational choices in the inappetent cat|journal=Journal of Feline Medicine and Surgery|date=September 2014|volume=16|issue=9|pages=749–56|doi=10.1177/1098612X14545273|pmid=25146662|s2cid=37126352}}</ref>
，也可作為[[哮喘|哮喘]]的輔助治療劑。<ref name=MVM2>{{cite book |author= Dowling PM |chapter= Systemic Therapy of Airway Disease: Cyproheptadine |chapter-url= http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190907.htm |veditors= Kahn CM, Line S, Aiello SE |title= The Merck Veterinary Manual |date= February 8, 2005 |publisher= [[John_Wiley_&_Sons|John Wiley & Sons]] |edition= 9th |isbn= 978-0-911910-50-6 |access-date= 2022-06-16 |archive-date= 2016-03-04 |archive-url= https://web.archive.org/web/20160304072415/http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm%2Fbc%2F190907.htm }} Retrieved on October 26, 2008.</ref>
可能的副作用包括刺激和攻擊行為。<ref name=MVM1>{{cite book |author= Dowling PM |chapter= Drugs Affecting Appetite |chapter-url= http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/190302.htm |veditors= Kahn CM, Line S, Aiello SE |title= The Merck Veterinary Manual |date= February 8, 2005 |publisher= [[John_Wiley_&_Sons|John Wiley & Sons]] |edition= 9th |isbn= 978-0-911910-50-6 |title-link= Merck Veterinary Manual |access-date= 2022-06-16 |archive-date= 2012-10-28 |archive-url= https://web.archive.org/web/20121028205743/http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm%2Fbc%2F190302.htm }} Retrieved on October 26, 2008.</ref>
塞浦西他啶（Cyproheptadine）在貓的[[生物半衰期|生物半衰期]]為 12 小時。<ref name=MVM2/>

塞浦西他啶（Cyproheptadine）也用在馬的{{link-en|垂體中間部功能障礙 |pituitary pars intermedia dysfunction}}的二線治療。<ref>{{cite journal|last1=Durham|first1=AE|title=Therapeutics for Equine Endocrine Disorders|journal=The Veterinary Clinics of North America. Equine Practice|date=April 2017|volume=33|issue=1|pages=127–139|doi=10.1016/j.cveq.2016.11.003|pmid=28190613}}</ref><ref>{{cite web|last=Merck Vet Manual|title=Hirsutism Associated with Adenomas of the Pars Intermedia|url=http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm/bc/40504.htm|access-date=April 24, 2011|archive-date=2016-03-03|archive-url=https://web.archive.org/web/20160303231300/http://www.merckvetmanual.com/mvm/index.jsp?cfile=htm%2Fbc%2F40504.htm}}</ref>

==參考資料==
{{Reflist|2}}

{{Antihistamines}}
<!--
{{Sedatives}}
{{Appetite stimulants}}
//-->
{{Navboxes
| title = [[Pharmacodynamics|Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Androgen receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Ion channel modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
<!--
{{Tricyclics}}
//-->

[[Category:抗雄激素物质|Category:抗雄激素物质]]
[[Category:抗组胺药物|Category:抗组胺药物]]
[[Category:抗精神病药|Category:抗精神病药]]
[[Category:Appetite_stimulants|Category:Appetite stimulants]]
[[Category:Dibenzocycloheptenes|Category:Dibenzocycloheptenes]]
[[Category:多巴胺拮抗药|Category:多巴胺拮抗药]]
[[Category:局部麻醉药|Category:局部麻醉药]]
[[Category:蕈毒碱性受体拮抗剂|Category:蕈毒碱性受体拮抗剂]]
[[Category:哌啶|Category:哌啶]]
[[Category:血清素拮抗剂|Category:血清素拮抗剂]]
[[Category:Sodium_channel_blockers|Category:Sodium channel blockers]]